HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications
- PMID: 20651405
HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications
Abstract
Aim: To assess HER-2 and p-AKT expression in upper urinary tract urothelial carcinoma (UTUC) in order to determine their value as prognostic factors of tumour progression and cancer-specific survival.
Patients and methods: One hundred consecutive UTUC patients were retrospectively included, between 1990-2004, in 4 tissue microarrays for immunostaining. Median follow-up: 33.03 months.
Results: Positive HER-2 expression was found in 10 cases and cytoplasmic p-AKT expression in 84 cases; the expression intensity was strong: 30 cases, moderate: 28 and weak: 26. Nuclear p-AKT expression was found in 6 patients: 1 with strong, and 5 with moderate intensity. Nuclear p-AKT expression was an independent factor for tumour progression (HR=4.145, p=0.013), together with grade (HR=4.557, p=0.009) and stage (HR=2.085, p=0.003). In cancer-specific survival analysis, nuclear p-AKT expression (HR=4.268, p=0.017), together with grade (HR=5.214, p=0.035) and stage (HR=2.666, p=0.002) were identified as independent prognostic factors.
Conclusion: Nuclear p-AKT expression together with stage and grade constitute independent prognostic factors for tumour progression and cancer-specific survival.
Similar articles
-
Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.BJU Int. 2006 Jun;97(6):1322-6. doi: 10.1111/j.1464-410X.2006.06158.x. BJU Int. 2006. PMID: 16686732
-
Adhesion molecules alpha, beta and gamma-catenin as prognostic factors of tumour progression in upper urinary tract urothelial tumours: the role of AKT-P/GSK-3beta/beta-catenin pathway.BJU Int. 2009 Jul;104(1):100-6. doi: 10.1111/j.1464-410X.2008.08292.x. Epub 2009 Jan 20. BJU Int. 2009. PMID: 19154502
-
Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.Urology. 2004 Jun;63(6):1079-83. doi: 10.1016/j.urology.2004.01.009. Urology. 2004. PMID: 15183954
-
Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.Hum Pathol. 2013 Dec;44(12):2668-76. doi: 10.1016/j.humpath.2013.07.008. Epub 2013 Sep 27. Hum Pathol. 2013. PMID: 24074531
-
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.Cancer. 2009 Mar 15;115(6):1224-33. doi: 10.1002/cncr.24135. Cancer. 2009. PMID: 19156917
Cited by
-
HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).World J Urol. 2017 Feb;35(2):251-259. doi: 10.1007/s00345-016-1871-x. Epub 2016 Jun 7. World J Urol. 2017. PMID: 27272502
-
Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study.Oncotarget. 2017 May 16;8(31):51522-51529. doi: 10.18632/oncotarget.17884. eCollection 2017 Aug 1. Oncotarget. 2017. PMID: 28881664 Free PMC article.
-
Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.World J Urol. 2017 Mar;35(3):337-353. doi: 10.1007/s00345-016-1826-2. Epub 2016 Apr 21. World J Urol. 2017. PMID: 27101100
-
Urothelial carcinomas: a focus on human epidermal receptors signaling.Am J Transl Res. 2011 Aug 15;3(4):362-73. Epub 2011 Jul 25. Am J Transl Res. 2011. PMID: 21904656 Free PMC article.
-
Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.Curr Urol Rep. 2016 Feb;17(2):12. doi: 10.1007/s11934-015-0566-y. Curr Urol Rep. 2016. PMID: 26757906 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous